CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Percentage of patients with type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly AdministRat…
DOI 10.1055/s-0035-1549748
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Adetunji, A Tahbaz, C Nicolay, K Khunti
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: We estimated the percentage of patients with baseline HbA1c ≥7.5% achieving HbA1c reduction ≥1% and weight loss ≥3% [NICE continuity criteria for glucagon-like peptide-1 (GLP-1) receptor agonists] after 26 weeks treatment with dulaglutide or exenatide, combined with oral antidiabetes medications. Methods: Post-hoc analysis was performed on pooled and individual study populations from two randomised stu…
Zitieren
Zitierempfehlung
O Adetunji, A Tahbaz, C Nicolay, K Khunti (2015) Percentage of patients with type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly AdministRation of dulaglutide in Diabetes (AWARD)-1 and -5 studies. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549748
Mit CareLit weiterarbeiten